You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

FDA Lifts Restrictions on Rosiglitazone

Aschenbrenner, Diane S. MS, RN

AJN, American Journal of Nursing:
doi: 10.1097/01.NAJ.0000445681.44930.17
Drug Watch
Abstract

* The Food and Drug Administration has lifted many of the restrictions it had placed on the type 2 antidiabetic drug rosiglitazone (Avandia) in 2011.

* Reevaluation of data from a major clinical trial indicated that rosiglitazone did not increase the risk of cardiovascular events as had been previously suggested.

Author Information

Diane S. Aschenbrenner recently retired as course coordinator for undergraduate pharmacology at Johns Hopkins University School of Nursing in Baltimore, MD. She also coordinates Drug Watch : daschen1@jhu.edu.

© 2014 Lippincott Williams & Wilkins. All rights reserved.